Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva Licenses Mersana Analog

by Lisa M. Jarvis
April 19, 2010 | A version of this story appeared in Volume 88, Issue 16

Mersana Therapeutics and Teva Pharmaceuticals have joined forces to develop XMT-1107, Mersana's novel fumagillin analog, which is expected to start Phase I trials in oncology this quarter. Teva will pay the development costs for XMT-1107, and Cambridge, Mass.-based Mersana could get up to $334 million in milestones if the drug candidate works across a range of indications. XMT-1107 prevents blood vessel growth and is linked to Mersana's Fleximer, a biodegradable polymer that improves the drug's safety and pharmacokinetic profile.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.